PROGNOSIS FACTORS AND TREATMENT TACTICS OF PATIENTS WITH UTERINE LEIOMYOSARCOMA
https://doi.org/10.17650/1994-4098-2008-0-1-45-51
Abstract
Surgery is the main method of treatment of the patients with the uterine leiomyosarcoma. A standard extent of surgery is extirpation of the uterus without its appendages in the reproductive period or with uterine appendages in the postmenopause. The comparative analysis of the remote results of the treatment of the patients depending on the radicality of the performed surgery let to find out that the presence of the resid- ual tumor in the minor pelvis significantly worsens the course and the prognosis of the disease in the patients with the uterine leiomyosarco- ma. The adjuvant therapy is worth using for the prophylaxis of the distant metastasizing in the patients with the uterine leiomyosarcoma in the presence the poor prognosis factors. The postoperative radiotherapy of the patients is ineffective due to the low radio sensitivity of the tumor. The poor prognosis factors are: postmenopause, age over 60 years, the presence of the residual tumor, invasion depth more than half of the myometrium, invasion of the tumor up to the tunica serosa uteri, tumor size more than 5 cm, tumor necroses, low grade of the tumor differ- entiation, mitoses rate more than 10 in 10 view fields. The vital prognosis of the patients with the distant metastases depends on their charac- ter. In case of solitary metastases — the prognosis is favorable, in patients with the multiple metastases the prognosis worsens essentially.
About the Authors
I. R. Gagua
Scientific and Research Institute of Clinical Oncology of N.N. Blokhin Cancer Research Center of Russian Academy of Medical Sciences
Russian Federation
Russian Federation
V. V. Kuznetzov
Scientific and Research Institute of Clinical Oncology of N.N. Blokhin Cancer Research Center of Russian Academy of Medical Sciences
Russian Federation
Russian Federation
N. I. Lazareva
Scientific and Research Institute of Clinical Oncology of N.N. Blokhin Cancer Research Center of Russian Academy of Medical Sciences
Russian Federation
Russian Federation
V. M. Nechushkina
Scientific and Research Institute of Clinical Oncology of N.N. Blokhin Cancer Research Center of Russian Academy of Medical Sciences
Russian Federation
Russian Federation
T. I. Zakharova
Scientific and Research Institute of Clinical Oncology of N.N. Blokhin Cancer Research Center of Russian Academy of Medical Sciences
Russian Federation
Russian Federation
Zh. A. Zavolskaya
Scientific and Research Institute of Clinical Oncology of N.N. Blokhin Cancer Research Center of Russian Academy of Medical Sciences
Russian Federation
Russian Federation
References
1. Harlow B. L., Weiss N.S., Lofton S. The epidemiology of sarcomas of the uterus. J Natl Cancer Inst 1986;76:339—402.
2. Leitao M. M., Brennan M. F., Hensley M. et al. Surgical resection of pulmonary and extrapulmonary recurrences of uterine leiomyosarcoma. Gynecol Oncol 2002;87:287—94.
3. Omura G.A., Blessing J.A., Major F. et al. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecological Oncology Group Study. J Clin Oncol 1985;3:1240—5.
4. Echr G., Jepson J., Steel J. et al. Treatment of uterine sarcomas. Cancer 1990;66(1):35—9.
5. Giuntoli R.L., Metzinger D.S., DiMarco C.S. et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol 2003;89:460—9.
6. Zaloudek C., Norris H.J. Mesenchymal tumors of the uterus. In: R.J. Kurman (ed). Blaustein's pathology of the female genital tract. New-York, Springer-Verlag; 1994. p. 487—528.
7. Parker W.H., Fu Y.S., Berek J.S. Uterine sarcoma in patients operated on for presumed leiomyoma in rapidly grow- ing leiomyoma. Obstet Gynecol 1994;83:414—8.
8. Platz C.E., Benda J.A. Female genital tract cancer. Cancer 1995;75:270—94.
9. Robboy S.J., Bentley R.C., Butnor K. et al. Pathology and pathophysiology of uter- ine smooth - muscle tumors. Environ Health Perspect 2000;108 (Suppl 5):779—84.
10. Лазарева Н.И. Злокачественные мезенхимальные опухоли женских половых органов: клиника, диагностика, лечение, факторы прогноза: Дис. ... Докт. мед. наук. М.; 2003. с. 68—118.
11. Aaro L.A., Symmonds R.E., Dockerty M.B. Sarcoma of the uterus: a clinical and pathologic study of 177 cases. Am J Obstet Gynecol 1966;94:101—9.
12. Blom R., Guerrieri C., Stal O. et al. Leiomyosarcoma of the uterus: a clinico- pathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases. Gynecol Oncol 1998;68:54—61.
13. Brooks S.E., Zhan M., Cote T. et al. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989—1999. Gynecol Oncol 2004;93:204—8.
14. Dinh T.A., Oliva E.A., Fuller Jr. A.F. et al. The treatment of uterine leiomyosarcoma. Result from a 10-year experience (1990-1999) at the Massachusetts General Hospital. Gynecologic Oncology 2004;92:648—52.
15. Livi L., Paiar F., Shah N. et al. Uterine sarcoma: twenty-seven years of experience. Int J Radiat Oncol Biol Phys 2003;57:1366—73.
16. Mayerhofer K., Obermair A., Windbichler G. et al. Leiomyosarcoma of the uterus: a clinicopathologic multicen- ter study of 71 cases. Gynecol Oncol 1999;74:196—201.
17. Nordal R.R., Kristensen G.B., Kaern J. et al. The prognostic significance of stage, tumor size, cellular atypia and DNA ploidy in uterine leiomyosarcoma. Acta Oncol 1995;34:797—802.
18. Hannigan E.V., Gomez L.G. Uterine leiomyosarcoma. Am J Obstet Gynecol 1979;134:557—64.
19. Major F.J., Blessing J.A., Silverberg S.G. et al. Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group Study. Cancer 1993;71 (Suppl 4):1702—9.
20. Peters W.A. 3rd, Howard D.R., Andersen W.A. et al. Uterine smooth-mus- cle tumors of uncertain malignant poten- tial. Obstet Gynecol 1994;83:1015—20.
21. Gadducci A., Landoni F., Sartori E. et al. Uterine Leiomyosarcoma: analysis of treatment failures and survival. Gynecol Oncol 1996;62:25—32.
22. Goff B.A., Rice L.W., Fleischhacker D. et al. Uterine leiomyosarcoma and endometrial stromal sarcoma: lymph node metastases and sites of recurrence. Gynecol Oncol 1993;50:105—9.
23. Tavassoli F.A., Devilee P. Mesenchymal tumours and related lesions of uterus. In: F.A. Tavassoli, P. Devilee (ed). World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Breast and Female Genital Organs. Lyon, I ARC Press; 2003. p. 233—45.
24. Leitao M., Sonoda Y., Brennan M.F. et al. Incidence of lymph node and ovari- an metastases in leiomyosarcoma of the uterus. Gynecol Oncol 2003;91:209—12.
25. Berchuck A., Rubin S.C., Hoskins W.J. et al. Treatment of uterine leiomyosarco- ma. Obstet Gynecol 1988;71:845—50.
26. Larson B., Silfversward C., Nilsson B. et al. Prognostic factors in uterine leiomyosarcoma: a clinical and histopathological study of 143 cases. The Radiumhemmet series 1936—1981. Acta Oncol 1990;29:185—91.
27. Wu T., Chang T., Hsueh S. et al. Prognostic factors and impact of adjuvant chemotherapy for uterine leiomyosarco- ma. Gynecol Oncol 2006;100:166—72.
28. Abu-Rustum N.R., Curtin J.P., Burt M. et al. Regression of uterine low-grade smooth-muscle tumors metastatic to the lung after oophorectomy. Obstet Gynecol 1997;89:850—2.
29. Belgrad R., Elbadawi N., Rubin P. Uterine sarcoma. Radiology 1975;114:181—8.
30. Perez C.A., Askin R.J. Effects of irra- diation on mixed mullerian tumors of the uterus. Cancer 1979;43:1274—84.
31. Salazar O.M., BonfiglioT.A., Patten S.F. et al. Uterine sarcomas: Natural history, treatment and prognosis. Cancer 1978;42:1152—60.
32. Knocke T.H., Kucera H., Dorfler N. et al. Results of postoperative radiothera- py in the treatment of sarcoma of the corpus uteri. Cancer 1998;83:1972—9.
Review
For citations:
Gagua I.R., Kuznetzov V.V., Lazareva N.I., Nechushkina V.M., Zakharova T.I., Zavolskaya Zh.A. PROGNOSIS FACTORS AND TREATMENT TACTICS OF PATIENTS WITH UTERINE LEIOMYOSARCOMA. Tumors of female reproductive system. 2008;(1):45-51. (In Russ.) https://doi.org/10.17650/1994-4098-2008-0-1-45-51
Views:
423
Email this article 